慢性肺源性心脏病患者采用安体舒通、托拉塞米治疗效果探究

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the clinical effect of Spironolactone and Torasemide in patients with chronic pulmonary heart disease.MethodsA total of 72 patients with chronic pulmonary heart disease who treated in our hospital from June 2015 to December 2016 were selected as objects and were randomly divided into control group and observation group according to the random number table method.There were 36 patients in each group.The control group was treated with Tonic and Diuretic and other conventional methods.The observation group was treated with Spironolactone and Torasemide on the basis of the control group.The clinical curative effect and cardiac function were compared between the two groups.ResultsThe total effective rate in the observation group was 97.22%and 83.33%in the control group,the difference was statistically significant(P＜0.05).Before treatment and after treatment,the cardiac function grading of the two groups was compared,the differences were not statistically significant(P＞0.05).After treatment,the patients ofⅡ level in the control group was more than before treatment,the patients ofⅣ level was less than before treatment,the difference was statistically significant(P＜0.05).After treatment,the patients ofⅡ level in the observation group was more than before treatment,the patients ofⅢandⅣlevel were less than before treatment,the difference was statistically significant (P＜0.05).ConclusionThe treatment of patients with chronic pulmonary heart disease by using Spironolactone and Tolosemide on the basis of the use of Tonic and Diuretics can effectively improve the patients′cardiac function,reduce the grade of cardiac function and improve the therapeutic effect.

Key words： Chronic pulmonary heart disease Spironolactone Torasemide Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG Xing-du
	WU Guo-bin

Cite this article:

ZENG Xing-du,WU Guo-bin. Study on the therapeutic effect of Spironolactone and Torasemide in patients with chronic pulmonary heart disease[J]. 中国当代医药, 2017, 24(30): 83-85.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I30/83

[1]	宋菲，张冬颖，刘剑，等.利尿剂在心力衰竭中的治疗进展[J].医学综述，2015，22（8）：1427-1429.
[2]	王俊彪.托拉塞米与呋塞米对比治疗慢性心力衰竭的疗效观察[J].辽宁医学院学报，2016，37（1）：42-44.
[3]	陈晓红.盐酸氨溴索注射液与托拉塞米注射液存在配伍禁忌[J].中华现代护理杂志，2015，21（11）：1351.
[4]	刘辉，王学惠，张永春，等.托拉塞米治疗慢性心力衰竭的临床观察[J].中国药房，2016，27（29）：4093-4095.
[5]	王海燕，吴雅梅.慢性肺源性心脏病患者的社区治疗与护理探究[J].中西医结合心血管病电子杂志，2014，2（8）：147.
[6]	陈广湛.卡托普利、安体舒通联合治疗慢性肺源性心脏病的研究[J].中国医药导刊，2014，16（3）：484-485.
[7]	Kido H，Ohtaki Y．Torasemide （LUPRAC）：areview ofits pharmaological and clinical profile[J].Nippon Yakurigaku Zasshi，2001，118（2）：97-105．
[8]	胡玲玲，任江华.托伐普坦与托拉塞米治疗慢性心衰急性发作的疗效比较[J].西南国防医药，2017，27（4）：338-340.
[9]	佟刚，王娉娉，周长宇，等.注射用硝普钠联合托拉塞米注射液与硝酸甘油注射液联合呋塞米注射液治疗老年慢性心力衰竭治疗效果的对比研究[J].实用心脑肺血管病杂志，2017，25（7）：66-69.
[10]	姚汉玲，蔡志芳，李青林，等.托拉塞米治疗慢性阻塞性肺病患者心力衰竭的临床分析 [J].临床肺科杂志，2016，21（3）：560-562.
[11]	雍苑，姬伟.托拉塞米注射液与注射用丹参多酚酸盐存在配伍禁忌[J].中华现代护理杂志，2016，22（15）：2121.
[12]	王艺润，方庆，郭晨辉，等.光谱法和分子对接模拟技术研究托拉塞米与胃蛋白酶和胰蛋白酶的相互作用[J].光谱学与光谱分析，2016，36（10）：3414-3421.
[13]	崔振川，王宏斌.托拉塞米和丹参酮ⅡA磺酸钠治疗慢性充血性心力衰竭的疗效比较 [J].现代药物与临床，2016，31（12）：1909-1912.
[14]	肖南海，林创明，康峰光，等.托拉塞米注射液治疗慢性心力衰竭急性加重期的疗效分析[J].吉林医学，2016，37（4）：779-781.
[15]	杜金勇，王功勋.托拉塞米序贯治疗对冠心病致慢性心衰心功能的影响[J].现代临床医学，2016，42（1）：31-33.